Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients

Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients

Abstract Immunotherapy has transformed the treatment landscape for non-small cell lung cancer (NSCLC), yet achieving lasting benefits remains a challenge. The resistance mechanisms to immunotherapy are complex, involving interactions between tumor cells and immune cells that are not fully understood...

Full description

Saved in:
Bibliographic Details
Main Authors: Luisa Amato, Caterina De Rosa, Gaetano Di Guida, Filippo Sepe, Annalisa Ariano, Sara Capaldo, Faiz Ul Haq, Alessandra Di Liello, Concetta Tuccillo, Stefano Lucà, Renato Franco, Viviana De Rosa, Francesca Iommelli, Alberto Servetto, Fortunato Ciardiello, Carminia Maria Della Corte, Floriana Morgillo
Format: Article
Language:English
Published: Nature Publishing Group 2025-04-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-025-07636-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41419-025-07636-7

Similar Items